vorasidenib
Selected indexed studies
- Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma. (N Engl J Med, 2023) [PMID:37272516]
- Vorasidenib: First Approval. (Drugs, 2024) [PMID:39375303]
- Vorasidenib and ivosidenib in IDH1-mutant low-grade glioma: a randomized, perioperative phase 1 trial. (Nat Med, 2023) [PMID:36823302]
_Worker-drafted node — pending editorial review._
Connections
vorasidenib is a side effect of
Sources
- Vorasidenib and ivosidenib in IDH1-mutant low-grade glioma: a randomized, perioperative phase 1 trial. (2023) pubmed
- Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma. (2023) pubmed
- Vorasidenib: First Approval. (2024) pubmed
- Vorasidenib, a Dual Inhibitor of Mutant IDH1/2, in Recurrent or Progressive Glioma; Results of a First-in-Human Phase I Trial. (2021) pubmed
- Vorasidenib for IDH-mutant grade 2 gliomas: clinical advances and future directions. (2025) pubmed
- The role of vorasidenib in the treatment of isocitrate dehydrogenase-mutant glioma. (2025) pubmed
- Vorasidenib (AG-881): A First-in-Class, Brain-Penetrant Dual Inhibitor of Mutant IDH1 and 2 for Treatment of Glioma. (2020) pubmed
- Vorasidenib in IDH1-mutant or IDH2-mutant low-grade glioma (INDIGO): secondary and exploratory endpoints from a randomised, double-blind, placebo-controlled, phase 3 trial. (2025) pubmed
- Open questions on vorasidenib. (2025) pubmed
- Vorasidenib: Patient and caregiver information sheet. (2025) pubmed